Incompatibility between donor and recipient for the Rhesus D (Rh D) red cell antigen occurs commonly in the setting of allogeneic hematopoietic SCT. Donor-derived immune reactions against host antigens or host immunity that persists despite the conditioning treatment may compromise the success of allogeneic transplantation. When such immune reactions involve RBC antigens, transfusion therapy for the patient may be complicated. Moreover, immunological tolerance between host and recipient occurs more gradually and may remain incomplete following reduced-intensity conditioning (RIC) compared with myeloablative regimens, and it remains unclear if alloimmunization occurs more commonly following Rh D-incompatible transplants in the RIC setting. Previous reports describe only occasional instances of Rh D alloimmunization after Rh D-incompatible transplants.
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We recently encountered a case of persistent anti-Rh D alloimmunization following allogeneic hematopoietic SCT, and reviewed our institutional experience for patients undergoing myeloablative conditioning and RIC allogeneic hematopoietic SCT to gain current insight regarding the incidence and potential clinical significance of Rh D alloimmunization in this setting.
A 56-year-old woman, diagnosed with AML in second CR, underwent allogeneic transplantation following myeloablative conditioning with CY, BU and antithymocyte antiglobulin. The patient, blood group A Rh D-negative, received PBSC from an unrelated HLA mis-matched (6/8) donor, blood group O Rh D-positive. The patient had evidence of prior Rh D alloimmunization before transplant, which was possibly related to transfusions administered following chemotherapy. The patient's blood group remained in transition for 4 months following transplantation and became donor type, blood group O Rh D-positive, thereafter. Following transplant, the patient developed significant hemolysis with a peak total bilirubin of 696 mmol/L on day 17 (direct bilirubin 619 mmol/L) after transplant that normalized by day 43. The peripheral blood film in the corresponding post-transplant period was characterized by abundant schistocytes, contracted RBC and ovalocytes without significant spherocytosis. The international normalized ratio and partial thromboplastin time, however, remained normal, and fibrinogen levels remained at or above the normal range, while repeated direct antiglobulin tests were positive for the presence of IgG. The lactate dehydrogenase peaked at 494 mmol/L on day 19 and was normalized by day 29. The aspartate aminotransferase and alanine transaminase levels remained less than twice the upper limit of normal. The patient required transfusion of 20 units of packed RBC within the first 22 days following transplant before RBC engraftment occurred. The patient did not exhibit any evidence of hemolysis in further follow-up, despite the persistence of a weak anti-Rh D that was þ 2 (on a scale of 0-4) at the time of last follow-up,16 months post transplant.
To gain insight into the incidence and consequences of RhDincompatible transplantation, we reviewed all patients undergoing allogeneic hematopoietic SCT at our institution from January 2000 through December 2010, and in whom Rh D mismatch between the patient and the donor existed. All patients, including the patient described above, provided consent for the use of medical information for research purposes in accordance with the research ethics board at our institution. We classified the conditioning regimens according to Cid et al. 3 into myeloablative conditioning (CY with TBI or BU-containing therapy) and RIC (fludarabine with BU or fludarabine with melphalan). Ab screening and identification was performed by our hospital blood bank using standard indirect antiglobulin techniques, such as tube testing (PEG; Dominion Biologicals, Dartmouth, Nova Scotia, Canada) or gel technology (MTS; Ortho-Clinical Diagnostics, Raritan, NJ, USA). All patients were screened twice weekly in the post-transplant period for indirect-acting RBC Abs until they achieved independence from RBC transfusions. Direct antiglobulin testing was only performed in cases of suspected hemolysis.
A total of 419 patients underwent allogeneic transplantation during the study period. Our study confirms that Rh D alloimmunization is uncommon following Rh D-incompatible allogeneic hematopoietic SCT. Moreover, commonly used RIC regimens do not appear to increase the risk of Rh D alloimmunization in susceptible patients. The lack of hemolysis beyond the period of RBC engraftment in the case described in this report suggests that Rh D alloimmunization does not adversely affect patients following major Rh D-incompatible allogeneic hematopoietic SCT. The paucity of cases describing Rh D alloimmunization after hematopoietic SCT is consistent with our findings. Moreover, two smaller studies did not reveal any instances of Rh D alloimmunization. Cid et al. 3 described 30 patients undergoing Rh D-incompatible allogeneic transplantation, and a separate smaller study revealed no cases following reduced-intensity transplantation. 4 In one previously published case, an Rh D-negative patient who was previously alloimmunized with Rh D prior to transplant received an Rh D-positive graft with subsequent disappearance of measurable anti-Rh D by day 38 post transplant. 5 A second case describes an Rh D-negative female with prior Rh D alloimmunization who received an Rh D-positive donor graft and developed hemolysis in the first weeks after transplant with subsequent disappearance of detectable anti-Rh D by 1 month post transplant. 6 The persistence of anti-Rh D for at least 16 months after transplant in the patient described in our report appears unique for major Rh D-incompatible transplants.
With respect to Rh D alloimmunization occurring after minor Rh-incompatible transplantation, one study described three out of seven Rh D-positive patients who received Rh D-negative grafts, and developed donor-derived anti-Rh D responses, which persisted for up to 1 year post transplant. 2 Only one of these patients experienced hemolysis, which peaked at day þ 13 post transplant. In our series of 36 patients with minor Rh D mismatches, we did not observe any cases of persistent anti-Rh D following transplant. As RIC regimens develop further, additional study and surveillance will be needed to understand the impact of Rh D incompatibility in the setting of different conditioning treatments. Moreover, the amount of previous chemotherapy prior to transplant may have a role in Rh D alloimmunization, and it would be interesting to study patients with non-malignant conditions who may have greater immune competency at the time of transplant.
In conclusion, Rh D alloimmunization is rare following myeloablative conditioning and RIC allogeneic hematopoietic SCT. The intensity of the conditioning regimen does not appear to increase the risk of Rh D alloimmunization. In rare cases of Rh D alloimmunization, clinical sequelae appear to be negligible beyond the period of RBC engraftment, and specific transfusion strategies for this population may not be required. 
